Suppression of T cell proliferation induced by concanavalin A in hemophilia patients. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Suppression of T cell proliferation induced by concanavalin A in hemophilia patients.

Medicina (B Aires). 1990;50(3):205-12. Unique Identifier : AIDSLINE MED/92017134
Sasiain MC; de la Barrera S; Ruibal Ares B; Picchio G; Muchinik G; Perez Bianco R; de Tezanos Pinto M; de Bracco MM; Instituto de Investigaciones Hematologicas, Academia Nacional de; Medicina, Buenos Aires, Argentina.

Abstract: Concanavalin A (Con-A)-induced suppression of T cell proliferation was studied in 48 patients with severe hemophilia. Two groups of patients were defined according to the proliferative response when increasing numbers of Con A-induced cells were added to a constant number of phytohemagglutinin (PHA)-stimulated autologous T cells: In group A (60%) and in normal controls, higher suppression was achieved when more Con A-induced cells were added; in Group B, increasing numbers of Con A-induced cells produced no suppression of stimulated PHA-triggered proliferation. This effect could be corrected in Group B by inducing suppression in the presence of inhibitors of the oxidative metabolism of arachidonic acid. No correlation was found between the suppression profile and HIV-1 or HBV serology. Clinical evolution, as judged by signs and symptoms of AIDS related complex tended to be better in Group B than in Group A patients. It is suggested that decreased Con A-induced suppression in Group B may represent part of a normal regulatory process that involves products of arachidonic acid oxidative metabolism.
Keywords: Adolescence Adult *Concanavalin A Hemophilia/*IMMUNOLOGY Human HIV Seropositivity/IMMUNOLOGY Lymphocyte Transformation/*DRUG EFFECTS Support, Non-U.S. Gov't T-Lymphocytes/*DRUG EFFECTS/IMMUNOLOGY JOURNAL ARTICLE

KWDadolescenceadultKWDconcanavalinahemophilia/KWDimmunologyhumanhivseropositivity/immunologylymphocytetransformation/KWDdrugeffectssupport,non-uKWDsKWDgov'tt-lymphocytes/KWDdrugeffects/immunologyjournalarticle
920130
M9210753

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .